Hemagglutinin Displayed Baculovirus Protects Against Highly Pathogenic Influenza

Vaccine

Volumn 28, Issue 42, 2010, Pages 6821-6831

  Tang, Xian Chun ^a,b   Lu, Hai Rong ^a   Ross, Ted M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Baculovirus display; H5N1; Influenza; Vaccine

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 64; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PROPIOLACTONE; SIGNAL PEPTIDE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACULOVIRUS; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; LETHAL DOSE; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTECTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; VACCINATION; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INSECTS; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PROPIOLACTONE; VACCINES, INACTIVATED;

EID: 77956875849     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.040     Document Type: Article

References (56)

1. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. The Lancet infectious diseases 2007 Oct, 7(10):658-666.
2. Blissard G.W. Baculovirus--insect cell interactions. Cytotechnology 1996, 20(1-3):73-93.
3. Miller L.K. Insect baculoviruses: powerful gene expression vectors. Bioessays 1989 Oct, 11(4):91-95.
4. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. Journal of virology 1993 Dec, 67(12):6929-6936.
5. Latham T., Galarza J.M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. Journal of virology 2001 Jul, 75(13):6154-6165.
6. Gheysen D., Jacobs E., de Foresta F., Thiriart C., Francotte M., Thines D., et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989 Oct 6, 59(1):103-112.
7. Kost T.A., Condreay J.P., Jarvis D.L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nature biotechnology 2005 May, 23(5):567-575.
8. Strauss R., Huser A., Ni S., Tuve S., Kiviat N., Sow P.S., et al. Baculovirus-based Vaccination Vectors Allow for Efficient Induction of Immune Responses Against Plasmodium falciparum Circumsporozoite Protein. Mol Ther 2007 Jan, 15(1):193-202.
9. Fan H., Pan Y., Fang L., Wang D., Wang S., Jiang Y., et al. Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice. Journal of virological methods 2008 Jun, 150(1-2):21-26.
10. Feng Q., Liu Y., Qu X., Deng H., Ding M., Lau T.L., et al. Baculovirus surface display of SARS coronavirus (SARS-CoV) spike protein and immunogenicity of the displayed protein in mice models. DNA and cell biology 2006 Dec, 25(12):668-673.
11. Lin Y.H., Lee L.H., Shih W.L., Hu Y.C., Liu H.J. Baculovirus surface display of sigmaC and sigmaB proteins of avian reovirus and immunogenicity of the displayed proteins in a mouse model. Vaccine 2008 Nov 25, 26(50):6361-6367.
12. Prabakaran M., Velumani S., He F., Karuppannan A.K., Geng G.Y., Yin L.K., et al. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 2008 Oct 25, 380(2):412-420.
13. Yoshida S., Kawasaki M., Hariguchi N., Hirota K., Matsumoto M. A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infection and immunity 2009 May, 77(5):1782-1789.
14. Boublik Y., Di Bonito P., Jones I.M. Eukaryotic virus display: engineering the major surface glycoprotein of the Autographa californica nuclear polyhedrosis virus (AcNPV) for the presentation of foreign proteins on the virus surface. Bio/technology (Nature Publishing Company) 1995 Oct, 13(10):1079-1084.
15. Oker-Blom C., Airenne K.J., Grabherr R. Baculovirus display strategies: Emerging tools for eukaryotic libraries and gene delivery. Briefings in functional genomics & proteomics 2003 Oct, 2(3):244-253.
16. Xu X.G., Liu H.J. Baculovirus surface display of E2 envelope glycoprotein of classical swine fever virus and immunogenicity of the displayed proteins in a mouse model. Vaccine 2008 Oct 9, 26(43):5455-5460.
17. Jin R., Lv Z., Chen Q., Quan Y., Zhang H., Li S., et al. Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori. PLoS ONE 2008, 3(12):e3933.
18. Prabakaran M., Madhan S., Prabhu N., Qiang J., Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. Journal of virology 2010 Apr, 84(7):3201-3209.
19. Yang D.G., Chung Y.C., Lai Y.K., Lai C.W., Liu H.J., Hu Y.C. Avian influenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential. Mol Ther 2007 May, 15(5):989-996.
20. Peralta A., Molinari P., Conte-Grand D., Calamante G., Taboga O. A chimeric baculovirus displaying bovine herpesvirus-1 (BHV-1) glycoprotein D on its surface and their immunological properties. Applied microbiology and biotechnology 2007 May, 75(2):407-414.
21. Monsma S.A., Blissard G.W. Identification of a membrane fusion domain and an oligomerization domain in the baculovirus GP64 envelope fusion protein. Journal of virology 1995 Apr, 69(4):2583-2595.
22. Oomens A.G., Blissard G.W. Requirement for GP64 to drive efficient budding of Autographa californica multicapsid nucleopolyhedrovirus. Virology 1999 Feb 15, 254(2):297-314.
23. Tani H., Nishijima M., Ushijima H., Miyamura T., Matsuura Y. Characterization of cell-surface determinants important for baculovirus infection. Virology 2001 Jan 5, 279(1):343-353.
24. Lu L., Yu L., Kwang J. Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity. Biochemical and biophysical research communications 2007 Jun 29, 358(2):404-409.
25. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle. PLoS ONE 2008, 3(1):e1501.
26. Wang K., Holtz K.M., Anderson K., Chubet R., Mahmoud W., Cox M.M. Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006 Mar 15, 24(12):2176-2185.
27. Chen B.J., Leser G.P., Morita E., Lamb R.A. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. Journal of virology 2007 Jul, 81(13):7111-7123.
28. Crevar C.J, Ross T.M. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virology journal 2008, 5:131.
29. Ross T.M., Mahmood K., Crevar C.J., Schneider-Ohrum K., Heaton P.M., Bright R.A. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS ONE 2009, 4(6):e6032.
30. Sakihama T., Sato T., Iwanari H., Kitamura T., Sakaguchi S., Kodama T., et al. A simple detection method for low-affinity membrane protein interactions by baculoviral display. PLoS ONE 2008, 3(12):e4024.
31. Makela A.R., Oker-Blom C. The baculovirus display technology--an evolving instrument for molecular screening and drug delivery. Combinatorial chemistry & high throughput screening 2008 Feb, 11(2):86-98.
32. Lindley K.M., Su J.L., Hodges P.K., Wisely G.B., Bledsoe R.K., Condreay J.P., et al. Production of monoclonal antibodies using recombinant baculovirus displaying gp64-fusion proteins. Journal of immunological methods 2000 Feb 3, 234(1-2):123-135.
33. Kitagawa Y., Tani H., Limn C.K., Matsunaga T.M., Moriishi K., Matsuura Y. Ligand-directed gene targeting to mammalian cells by pseudotype baculoviruses. Journal of virology 2005 Mar, 79(6):3639-3652.
34. Rapoport TA. Transport of proteins across the endoplasmic reticulum membrane. Science (New York, NY 1992 Nov 6;258(5084):931-6.
35. Li Z., Blissard G.W. Functional analysis of the transmembrane (TM) domain of the Autographa californica multicapsid nucleopolyhedrovirus GP64 protein: substitution of heterologous TM domains. J Virol 2008 Apr, 82(7):3329-3341.
36. Lazarovits J., Shia S.P., Ktistakis N., Lee M.S., Bird C., Roth M.G. The effects of foreign transmembrane domains on the biosynthesis of the influenza virus hemagglutinin. The Journal of biological chemistry 1990 Mar, 265(8):4760-4767.
37. Schnell M.J., Buonocore L., Boritz E., Ghosh H.P., Chernish R., Rose J.K. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. The EMBO journal 1998 Aug 10, 17(5):1289-1296.
38. Suomalainen M., Liljestrom P., Garoff H. Spike protein-nucleocapsid interactions drive the budding of alphaviruses. Journal of virology 1992 Aug, 66(8):4737-4747.
39. Roth M.G., Doyle C., Sambrook J., Gething M.J. Heterologous transmembrane and cytoplasmic domains direct functional chimeric influenza virus hemagglutinins into the endocytic pathway. The Journal of cell biology 1986 Apr, 102(4):1271-1283.
40. Doyle C., Sambrook J., Gething M.J. Analysis of progressive deletions of the transmembrane and cytoplasmic domains of influenza hemagglutinin. The Journal of cell biology 1986 Oct, 103(4):1193-1204.
41. Hervas-Stubbs S., Rueda P., Lopez L., Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J Immunol 2007 Feb 15, 178(4):2361-2369.
42. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., et al. Update on avian influenza A (H5N1) virus infection in humans. The New England journal of medicine 2008 Jan 17, 358(3):261-273.
43. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A. Cytotoxic T-cell immunity to influenza. The New England journal of medicine 1983 Jul 7, 309(1):13-17.
44. Graham M.B., Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. The Journal of experimental medicine 1997 Dec 15, 186(12):2063-2068.
45. Hikono H., Kohlmeier J.E., Ely K.H., Scott I., Roberts A.D., Blackman M.A., et al. T-cell memory and recall responses to respiratory virus infections. Immunological reviews 2006 Jun, 211:119-132.
46. Kedzierska K., La Gruta N.L., Turner S.J., Doherty P.C. Establishment and recall of CD8+ T-cell memory in a model of localized transient infection. Immunological reviews 2006 Jun, 211:133-145.
47. Flynn K.J., Belz G.T., Altman J.D., Ahmed R., Woodland D.L., Doherty P.C. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998 Jun, 8(6):683-691.
48. Thomas P.G., Keating R., Hulse-Post D.J., Doherty P.C. Cell-mediated protection in influenza infection. Emerging infectious diseases 2006 Jan, 12(1):48-54.
49. Heiny A.T., Miotto O., Srinivasan K.N., Khan A.M., Zhang G.L., Brusic V., et al. Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS ONE 2007, 2(11):e1190.
50. Lee L.Y., Ha do L.A., Simmons C., de Jong M.D., Chau N.V., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. The Journal of clinical investigation 2008 Oct, 118(10):3478-3490.
51. Abe T., Kaname Y., Wen X., Tani H., Moriishi K., Uematsu S., et al. Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. Journal of virology 2009 Aug, 83(15):7629-7640.
52. Abe T., Takahashi H., Hamazaki H., Miyano-Kurosaki N., Matsuura Y., Takaku H. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J Immunol 2003 Aug 1, 171(3):1133-1139.
53. Nishibe Y., Kaneko H., Suzuki H., Abe T., Matsuura Y., Takaku H. Baculovirus-mediated interferon alleviates dimethylnitrosamine-induced liver cirrhosis symptoms in a murine model. Gene therapy 2008 Jul, 15(13):990-997.
54. Quan F.S., Huang C., Compans R.W., Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. Journal of virology 2007 Apr, 81(7):3514-3524.
55. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005 Dec 30, 23(50):5751-5759.
56. Kenoutis C., Efrose R.C., Swevers L., Lavdas A.A., Gaitanou M., Matsas R., et al. Baculovirus-mediated gene delivery into Mammalian cells does not alter their transcriptional and differentiating potential but is accompanied by early viral gene expression. Journal of virology 2006 Apr, 80(8):4135-4146.